

Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/O7745E04ECC5EN.html

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: 07745E04ECC5EN

Abstracts

The 7 major obsessive-compulsive disorder markets reached a value of US\$ 643.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,078.4 Million by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.

The obsessive-compulsive disorder market has been comprehensively analyzed in IMARC's new report titled "Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obsessive-compulsive disorder (OCD) refers to a mental health condition characterized by intrusive, recurrent thoughts (obsessions) and repetitive, ritualistic behaviors or mental acts that patients feel compelled to perform. This disease causes significant distress and can interfere with daily functioning, relationships, and the overall quality of life. The common symptoms of the ailment include fear of losing control, concerns about order, symmetry or exactness, counting or tapping rituals, anxiety, agitation, a sense of guilt or shame, aggression, intense stress, etc. Individuals suffering from the disorder may additionally experience impulsivity, repetitive movements, social isolation, compulsive hoarding, panic attacks, depression, food aversion, nightmares, etc. OCD is typically diagnosed through a combination of clinical evaluation, assessment of indications, and neurological tests. The healthcare professional will validate a diagnosis by referring to the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Various other self-report questionnaires or rating scales may be used to determine the frequency and severity of disease symptoms. These scales include the Yale-brown obsessive-compulsive scale, the obsessive-compulsive inventory, the dimensional obsessive-compulsive scale, etc.

The rising prevalence of imbalances in specific neurotransmitters, such as serotonin,



dopamine, glutamate, etc., that can lead to abnormalities in brain structure and functioning is primarily driving the obsessive-compulsive disorder market. In addition to this, the increasing incidences of several associated risk factors, including certain neurological conditions, traumatic events, chronic stress, genetic mutations, etc., are further augmenting the market growth. Moreover, the emerging popularity of selective serotonin reuptake inhibitors (SSRIs), such as sertraline and fluoxetine, which work by inhibiting neurochemical reuptake and providing symptom relief among patients, is also creating a positive outlook for the market. Apart from this, the widespread adoption of habit reversal training procedures that aid individuals suffering from OCD to regain a sense of control over their thoughts and actions is further bolstering the market growth. Additionally, the escalating utilization of dialectical behavior therapy, since it combines cognitive-behavioral techniques with mindfulness and emotional regulation strategies to enhance distress tolerance and reduce compulsiveness in patients, is expected to drive the obsessive-compulsive disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the obsessive-compulsive disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obsessive-compulsive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obsessive-compulsive disorder market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023 Market Forecast: 2024-2034

Countries Covered

United States Germany



France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the obsessive-compulsive disorder market Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the obsessive-compulsive disorder market Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current obsessive-compulsive disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:



Market Insights

How has the obsessive-compulsive disorder market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the obsessive-compulsive disorder market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the obsessive-compulsive disorder market across the seven major markets and what will be the expected growth over the next ten years? What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder across the seven major markets?

What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with obsessive-compulsive disorder across the seven major markets?

What is the size of the obsessive-compulsive disorder patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of obsessive-compulsive disorder?

What will be the growth rate of patients across the seven major markets?

Obsessive-Compulsive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance? What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for obsessive-compulsive disorder drugs



across the seven major markets?

Who are the key companies in the market and what are their market shares? What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obsessive-compulsive disorder market?

What are the key regulatory events related to the obsessive-compulsive disorder market?

What is the structure of clinical trial landscape by status related to the obsessive-compulsive disorder market?

What is the structure of clinical trial landscape by phase related to the obsessive-compulsive disorder market?

What is the structure of clinical trial landscape by route of administration related to the obsessive-compulsive disorder market?



Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 OBSESSIVE-COMPULSIVE DISORDER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 OBSESSIVE-COMPULSIVE DISORDER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 OBSESSIVE-COMPULSIVE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION



- 7.1 Epidemiology Key Insights
- 7.2 Epidemiology Scenario Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)
 - 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario Italy
- 7.7.1 Epidemiology Scenario (2018-2023)
- 7.7.2 Epidemiology Forecast (2024-2034)



- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.6 Diagnosed Cases (2018-2034)
- 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario Japan
- 7.9.1 Epidemiology Scenario (2018-2023)
- 7.9.2 Epidemiology Forecast (2024-2034)
- 7.9.3 Epidemiology by Age (2018-2034)
- 7.9.4 Epidemiology by Gender (2018-2034)
- 7.9.6 Diagnosed Cases (2018-2034)
- 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 OBSESSIVE-COMPULSIVE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 OBSESSIVE-COMPULSIVE DISORDER - UNMET NEEDS

10 OBSESSIVE-COMPULSIVE DISORDER - KEY ENDPOINTS OF TREATMENT

11 OBSESSIVE-COMPULSIVE DISORDER - MARKETED PRODUCTS

- 11.1 List of Obsessive-Compulsive Disorder Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Zoloft (Sertraline) Pfizer
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Prozac (Fluoxetine) Eli Lilly



- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Luvox (Fluvoxamine)
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Paxil (Paroxetine) Novo Nordisk
- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 OBSESSIVE-COMPULSIVE DISORDER - PIPELINE DRUGS

- 12.1 List of Obsessive-Compulsive Disorder Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 BHV4157 Biohaven Pharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 SYNP 101 Ceruvia Lifesciences
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. OBSESSIVE-COMPULSIVE DISORDER - ATTRIBUTE ANALYSIS OF KEY



MARKETED AND PIPELINE DRUGS

14. OBSESSIVE-COMPULSIVE DISORDER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 OBSESSIVE-COMPULSIVE DISORDER - MARKET SCENARIO

- 15.1 Market Scenario Key Insights
- 15.2 Market Scenario Top 7 Markets
 - 15.2.1 Obsessive-Compulsive Disorder Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario United States
 - 15.3.1 Obsessive-Compulsive Disorder Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.4 Market Scenario Germany
 - 15.4.1 Obsessive-Compulsive Disorder Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.5 Market Scenario France
 - 15.5.1 Obsessive-Compulsive Disorder Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)



- 15.5.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.6 Market Scenario United Kingdom
 - 15.6.1 Obsessive-Compulsive Disorder Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.7 Market Scenario Italy
 - 15.7.1 Obsessive-Compulsive Disorder Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.8 Market Scenario Spain
 - 15.8.1 Obsessive-Compulsive Disorder Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview
- 15.9 Market Scenario Japan
 - 15.9.1 Obsessive-Compulsive Disorder Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Obsessive-Compulsive Disorder Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Obsessive-Compulsive Disorder Access and Reimbursement Overview

16 OBSESSIVE-COMPULSIVE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS



17 OBSESSIVE-COMPULSIVE DISORDER MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 OBSESSIVE-COMPULSIVE DISORDER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX



I would like to order

Product name: Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size,

Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/O7745E04ECC5EN.html

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O7745E04ECC5EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



